U083 - Field Cancerization Therapies: Medical Dermatology and Beyond
Monday, March 4; 7:30 AM - 8:30 AM
Following this course, the attendee should be able to:
- Define the field cancerization concept
- Determine standard of care field therapies for AKs and Non-Melanoma Skin Cancers, applied as mono therapies or combinations
- Select the right candidates for field directed therapies in elderly and high risk patients
Field cancerization theory postulates that the skin surrounding actinic keratoses (AKs) is at increased risk for possible precancerous changes and malignant transformation. Field-directed therapies have the potential to target clinically evident and subclinically damaged skin, reduce AK recurrences, and possibly reduce NMSC risk and particularly SCCs, in elderly and chronically immunosuppressed patients. This session will outline the standard of care field therapies including topical 5- fluorouracil, imiquimod, diclofenac, piroxicam, ingenol mebutate, conventional and daylight photodynamic therapy. Clinical algorithms, outcomes and potency of these field directed therapies as monotherapies or in combination, will be evaluated.
- Konnikov, Nellie, MD: no financial relationships exist with commercial interests.
- Tsoukas, Maria M., MD, PhD: American Society of Dermatologic Surgery – I(Grants/Research Funding); Biofrontera AG – A(H);
All faculty / Field Cancerization Therapies: Medical Dermatology and Beyond